Medicine and Dentistry
Combination Therapy
33%
Elderly Patient
100%
Lymphoma
33%
Maintenance Therapy
33%
Methotrexate
33%
Overall Survival
33%
Patient
33%
Primary Central Nervous System Lymphoma
66%
Procarbazine
33%
Progression Free Survival
33%
Rituximab
33%
Temozolomide
100%
Toxicity
33%
Vincristine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Lymphoma
33%
Methotrexate
33%
Overall Survival
33%
Primary Central Nervous System Lymphoma
66%
Procarbazine
33%
Progression Free Survival
33%
Rituximab
33%
Temozolomide
100%
Toxicity
33%
Vincristine
33%
Neuroscience
Lymphoma
33%
Methotrexate
33%
Primary Central Nervous System Lymphoma
66%
Procarbazine
33%
Rituximab
33%
Temozolomide
100%
Vincristine
33%
Biochemistry, Genetics and Molecular Biology
Methotrexate
33%
Overall Survival
33%
Procarbazine
33%
Progression Free Survival
33%
Rituximab
33%
Immunology and Microbiology
Methotrexate
33%
Overall Survival
33%
Progression Free Survival
33%
Rituximab
33%